865,349 Shares in Teladoc Health, Inc. $TDOC Acquired by Freestone Grove Partners LP

Freestone Grove Partners LP purchased a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 865,349 shares of the health services provider’s stock, valued at approximately $7,338,000. Freestone Grove Partners LP owned approximately 0.48% of Teladoc Health at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of TDOC. Renaissance Technologies LLC boosted its stake in Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after purchasing an additional 107,400 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock valued at $52,459,000 after buying an additional 605,061 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Teladoc Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after buying an additional 18,394 shares during the last quarter. Jupiter Asset Management Ltd. raised its holdings in shares of Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after buying an additional 2,880,008 shares during the last quarter. Finally, Pale Fire Capital SE lifted its position in Teladoc Health by 74.8% during the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after buying an additional 1,454,288 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.

Analyst Ratings Changes

TDOC has been the topic of a number of research analyst reports. Canaccord Genuity Group decreased their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Bank of America upped their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Finally, Citigroup lowered their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a report on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.54.

Insider Buying and Selling

In other news, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the transaction, the insider owned 9,572 shares of the company’s stock, valued at $73,034.36. This represents a 37.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the transaction, the insider owned 57,671 shares in the company, valued at $440,029.73. This represents a 9.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 39,195 shares of company stock worth $299,058. Company insiders own 0.70% of the company’s stock.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $6.51 on Friday. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -6.58 and a beta of 2.12. The company has a 50 day moving average of $7.94 and a 200-day moving average of $6.64. Teladoc Health, Inc. has a one year low of $4.40 and a one year high of $9.89.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same period in the prior year, the business posted ($0.19) earnings per share. Teladoc Health’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts anticipate that Teladoc Health, Inc. will post -0.89 earnings per share for the current year.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.